IL-2在原发性肝癌中的作用及潜在临床应用价值

doi:10.3760/cma.j.issn.1673-422X.2015.12.015

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (12): 939-941.doi: 10.3760/cma.j.issn.1673-422X.2015.12.015

IL-2在原发性肝癌中的作用及潜在临床应用价值

庞婧,邓志华

030001 太原，山西医科大学第二医院消化内科

出版日期:2015-12-08 发布日期:2015-11-10
通讯作者: 邓志华 E-mail:ykdzh@hotmail.com
基金资助:
山西省自然科学基金（2012011038-6）

Effect of IL-2 on primary hepatic carcinoma and its potential clinical value

Pang Jing, Deng Zhihua

Department of Gastroenterology, Second Hospital of Shanxi Medical University, Taiyuan 030001, China

Online:2015-12-08 Published:2015-11-10
Contact: Deng Zhihua E-mail:ykdzh@hotmail.com

摘要/Abstract

摘要： 作为T淋巴细胞亚群生长因子，白细胞介素2（IL2）一方面可有效抑制癌细胞增殖、降低致瘤性及转移性、改善癌组织局部微环境、增强癌细胞抗原性、降低肝炎病毒载量、强化机体抗肿瘤能力。另一方面IL2增强了肿瘤的高凝状态。IL2对于原发性肝癌的作用及其潜在临床应用价值有光明的研究前景。

关键词: 白细胞介素2, 肝肿瘤, 临床意义

Abstract: As a T cell subsets growth factor, interleukin-2 (IL-2) can inhibit cancer cell proliferation, reduce tumorigenicity and transitivity, improve local tumor microenvironment, enhance the immunogenicity of hepatocellular carcinoma cells, reduce the load of hepatitis virus and greatly enhance the ability of antitumor. On the other hand, it can enhance tumor hypercoagulable state. The effect of IL-2 on primary hepatic carcinoma and its potential clinical value have a bright future.

Key words: Interleukin 2, Liver neoplasms, Clinical significance

庞婧,邓志华. IL-2在原发性肝癌中的作用及潜在临床应用价值[J]. 国际肿瘤学杂志, 2015, 42(12): 939-941.

Pang Jing, Deng Zhihua. Effect of IL-2 on primary hepatic carcinoma and its potential clinical value[J]. Journal of International Oncology, 2015, 42(12): 939-941.

参考文献

［1］ Teng MW, von Scheidt B, Duret H, et al. AntiIL23 monoclonal antibody synergizes in combination with targeted therapies or IL2 to suppress tumor growth and metastases［J］. Cancer Res, 2011, 71(6): 2077-2086. ［2］ Xu HM. Th1 cytokinebased immunotherapy for cancer［J］. Hepatobiliary Pancreat Dis Int, 2014, 13(5): 482-494. ［3］ Weiss JM, Subleski JJ, Back T, et al. Regulatory T cells and myeloidderived suppressor cells in the tumor microenvironment undergo Fasdependent cell death during IL2/aCD40 therapy［J］. J Immunol, 2014, 192(12): 5821-5829. ［4］ Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms and implications to cancer immunotherapy［J］. Ann NY Acad Sci, 2013, 1284: 1-5. ［5］ Kakita N, Kanto T, Itose I, et al. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-)FOXP3(-) T cells［J］. Int J Cancer, 2012, 131(11): 2573-2583. ［6］ Xiao G, Deng A, Liu H, et al. Activator protein 1 suppresses antitumor Tcell function via the induction of programmed death 1［J］. Proc Natl Acad Sci USA, 2012, 109(38): 15419-15424. ［7］ Kozowska A, Mackiewicz J, Mackiewicz A. Therapeutic gene modified cell based cancer vaccines［J］. Gene, 2013, 525(2): 200-207. ［8］ Yang JY, Li X, Gao L, et al. Cotransfection of dendritic cells with AFP and IL2 genes enhances the induction of tumor antigenspecific antitumor immunity［J］. Exp Ther Med, 2012, 4(4): 655-660. ［9］ Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro［J］. J Immunol, 2009, 183(12): 8286-8294. ［10］ Tomova R, Antonov K, Ivanova A, et al. Lowdose IL2 therapy reduces HCV RNA and HBV DNA: case report［J］. Anticancer Res, 2009, 29(12): 5241-5244. ［11］ Zhang X, Wei HX, Rui S, et al. Opposite effects of high and low doses of interleukin2 on T cellmediated hepatitis in mice (interleukin2 on hepatitis)［J］. Hepatol Int, 2010, 4(3): 641-648. ［12］ Su K, Chen F, Yan WM, et al. Fibrinogenlike protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL2 and IFNgamma［J］. World J Gastroenterol, 2008, 14(39): 5980-5989. ［13］ Cabrera R, Ararat M, Cao M, et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25)［J］. Dig Dis Sci, 2010, 55(2): 484-495. ［14］ Chen JD, Xiong YQ, Dong K, et al. Clinical significance of joint detection of serum VEGF, SIL2R and HGF in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy［J］. Asian Pac J Cancer Prev, 2014, 15(11): 4545-4548. ［15］ Seidler S, Zimmermann HW, Weiskirchen R, et al. Elevated circulating soluble interleukin2 receptor in patients with chronic liver diseases is associated with nonclassical monocytes［J］. BMC Gastroenterol, 2012, 12: 38. ［16］ Cabrera R, Ararat M, Eksioglu EA, et al. Influence of serum and soluble CD25 (sCD25) on regulatory and effector Tcell function in hepatocellular carcinoma［J］. Scand J Immunol, 2010, 72(4): 293-301. ［17］王鹤, 邓志华. 乙肝病毒衣壳运载体甲胎蛋白启动子驱动的白细胞介素2在肝癌细胞中的靶向表达［J］. 肿瘤研究与临床, 2014, 26(1): 20-23.

[1]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[3]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[4]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[5]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[6]	和婷, 王希, 张惠中, 刘昕阳, 王会平, 董轲. 血清TIM-3对肝癌患者诊断价值的研究[J]. 国际肿瘤学杂志, 2022, 49(9): 537-542.
[7]	张玉敏, 赵现伟, 何前进, 陈杰能. 超声造影联合血清CXCL8、CXCR2在原发性肝癌经导管动脉化疗栓塞术后疗效评估中的价值分析[J]. 国际肿瘤学杂志, 2022, 49(10): 592-596.
[8]	狄伟华, 赵雪梅. DNA损伤修复在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 635-638.
[9]	杜佳航, 陈栋, 陈耀庭. 三氧化二砷抗肝癌机制及其在肝癌治疗中的研究[J]. 国际肿瘤学杂志, 2021, 48(9): 572-.
[10]	韩保俊. 组蛋白乙酰转移酶P300在肝癌组织中的表达及其临床意义[J]. 国际肿瘤学杂志, 2021, 48(7): 415-419.
[11]	张玉元, 李臻, 詹鹏超, 李鑫, 叶书文, 王彩鸿, 刘杨. 肝癌标志物研究进展[J]. 国际肿瘤学杂志, 2021, 48(4): 241-245.
[12]	熊琳, 张修云, 张小余, 黎越, 徐细明. IWR-1-endo通过抑制Wnt通路影响肝癌细胞的迁移和增殖[J]. 国际肿瘤学杂志, 2021, 48(12): 711-715.
[13]	刘俊国, 张金卷, 王毅军. ALPPS中肝脏离断技术变异的临床应用进展[J]. 国际肿瘤学杂志, 2020, 47(8): 492-495.
[14]	张伟, 殷海涛, 周冲, 李向阳, 郭林. 甲磺酸阿帕替尼联合卡瑞利珠单抗治疗原发性肝癌伴肺转移一例[J]. 国际肿瘤学杂志, 2020, 47(8): 510-512.
[15]	辛瑞强, 宋晓萍, 张帆, 孙莹, 王涛, 孙伟. SUMO调控XBP1介导的内质网应激对肝癌进展的影响机制[J]. 国际肿瘤学杂志, 2020, 47(7): 397-403.

IL-2在原发性肝癌中的作用及潜在临床应用价值

Effect of IL-2 on primary hepatic carcinoma and its potential clinical value

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价